Evidence map›Paper›PMID 42633648›Full record

ArticleVirulence2026

Targeted degradation of Influenza a virus nucleoprotein via aptamer-based PROTACs for antiviral therapy.

Weiqiang Li, Yong Ju, Yaoyao Gao, Jinkun Peng, Nan Qi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virulence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Weiqiang LiState Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.ORCID 0000-0002-8643-359X
Yong JuDepartment of Basic Research, Guangzhou National Laboratory, Guangzhou, China.
Yaoyao GaoDepartment of Basic Research, Guangzhou National Laboratory, Guangzhou, China.
Jinkun PengState Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Nan QiState Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.ORCID 0000-0002-1423-7709

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Influenza A virus (IAV) poses a serious threat to public health due to its high mutability and rapid transmissibility. The viral nucleoprotein (NP), a highly conserved and essential component, has emerged as an ideal target for antiviral therapies. However, its biological function has proven challenging to modulate with conventional drugs, and no NP-targeting therapeutics have reached the market so far. Here, we report the development and application of an aptamer-based proteolysis-targeting chimera (PROTAC) for the targeted degradation of IAV NP. Utilizing the Direct-to-Biology (D2B) platform, we efficiently screened and identified NP-PROTAC#4 as a functional candidate. Subsequently, we developed a lipid nanoparticle (LNP) formulation of NP‑PROTAC#4 (LNP@NP‑PROTAC#4) for effective intracellular delivery. Importantly, LNP@NP-PROTAC#4 demonstrated potent antiviral activity both

Indexed as

Antiviral AgentsAptamers, NucleotideInfluenza A virusNucleoproteinsRNA-Binding ProteinsViral Core ProteinsAnimalsDogsHumansMiceNanoparticlesNucleocapsid ProteinsOrthomyxoviridae InfectionsProteolysisProteolysis Targeting ChimeraAntiviral AgentsAptamers, NucleotideNP protein, Influenza A virusNucleocapsid ProteinsNucleoproteinsProteolysis Targeting ChimeraRNA-Binding ProteinsViral Core Proteinsantiviral therapyaptamerInfluenza a virusnucleoproteinproteolysis-targeting chimera

Identifiers

PMID42633648
PMCPMC13502000

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.